This trial is testing a new medication to see if it can help kids with sickle cell disease. The goal is to see if it can reduce problems with blood flow in the brain.
- Sickle Cell Disease
1 Primary · 9 Secondary · Reporting Duration: 24, 48 and 96 weeks
2 Treatment Groups
1 of 2
1 of 2
236 Total Participants · 2 Treatment Groups
Primary Treatment: Voxelotor · Has Placebo Group · Phase 3
Who is running the clinical trial?
Age 2 - 14 · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there other instances of Voxelotor being used in medical research?
"Currently, there are 7 different active studies investigating Voxelotor with 3 of them in Phase 3. Some of the clinical trials related to Voxelotor are happening in Philadelphia, Pennsylvania; however, there are a total of 139 locations running trials for Voxelotor." - Anonymous Online Contributor
How many people are currently testing this treatment?
"In total, 224 patients that meet the specific inclusion criteria are needed for this clinical trial. Patients have the choice to participate in this trial at University of Miami Medical Center in Miami, Florida or University of Mississippi Medical Center in Jackson, Mississippi." - Anonymous Online Contributor
Are people of an older age bracket still being allowed to enroll in this research?
"Eligible participants for this clinical study must be aged 2-14, as stated in the inclusion criteria." - Anonymous Online Contributor
Who would be an ideal candidate to take part in this clinical trial?
"To qualify for this trial, applicants must be aged 2-14, have anemia, and sickle cell. Additionally, the applicant must be either male or female." - Anonymous Online Contributor
Are there any available spots left for participants in this research?
"The information available on clinicaltrials.gov seems to suggest that this study is currently looking for participants. The trial was first posted on 4/7/2021 and was last updated on 8/16/2022. The study is admitting a total of 224 participants at 10 sites." - Anonymous Online Contributor
Have other research teams looked into this same topic previously?
"Research into Voxelotor began in 2016. The first, sponsored by Global Blood Therapeutics, 155-person study was completed that year. Based on the data from that initial study, Voxelotor received approval for Phase 2 clinical trials. There are currently 7 active studies involving Voxelotor taking place in 39 cities across 14 countries." - Anonymous Online Contributor
Are there Voxelotor side effects that patients should be made aware of?
"Given that this is a Phase 3 trial with some efficacy data and multiple rounds of safety data, we at Power rate the safety of Voxelotor as a 3." - Anonymous Online Contributor